10-Q: PACS Group Q1 2025: Revenue Growth Amidst Legal Challenges

PACS Group reports significant revenue growth in Q1 2025, driven by facility expansion, but faces ongoing SEC and DOJ investigations and internal control weaknesses.

Summary

• Total revenue increased by 38.8% to $1.277 billion for the three months ended March 31, 2025, compared to $919.836 million in the prior year (as restated).
• Net income decreased by 18.5% to $28.380 million for Q1 2025, down from $34.819 million in Q1 2024 (as restated).
• Operating income declined by 26.3% to $48.140 million in Q1 2025, from $65.309 million in Q1 2024 (as restated).
• The company's operational footprint expanded significantly, with the total number of facilities increasing by 79.0% to 315 and operational beds by 32.9% to 34,553 as of March 31, 2025, compared to March 31, 2024.
• Overall occupancy rate for skilled nursing services decreased to 89.2% in Q1 2025 from 91.1% in Q1 2024, driven by decreases in both New and Ramping facility cohorts.
• General and administrative expenses surged by 110.5% to $98.7 million, primarily due to a $22.8 million increase in legal fees related to investigations and $12.2 million in stock-based compensation expense.
• The company identified material weaknesses in its internal control over financial reporting, specifically in its control environment and revenue recognition processes, leading to a restatement of prior financial statements.
• Multiple ongoing regulatory investigations by the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) are disclosed, related to alleged False Claims Act violations, Anti-Kickback Statute, COVID-19 waivers, and accounting practices.
• The company entered into several forbearance agreements with its lenders due to technical events of default under its Amended and Restated Credit Facility and the Omega Master Lease.

Sentiment

Score: 3

Explanation: While revenue growth and operational expansion are positive, the significant decline in net income and operating income, coupled with the restatement, identified material weaknesses, multiple ongoing regulatory investigations (DOJ, SEC), and class-action lawsuits, indicate severe operational and governance challenges. The forbearance agreements with lenders further highlight financial instability and compliance issues, leading to a negative outlook.

Positives

• Total revenue increased by 38.8% to $1.277 billion for the three months ended March 31, 2025, demonstrating strong top-line growth.
• Skilled nursing services revenue grew by 37.4%, or $341.5 million, driven by a 31.2% increase in patient days and a 32.9% increase in operational beds.
• Net cash provided by operating activities significantly increased by $91.5 million to $150.2 million for Q1 2025, compared to $58.751 million in Q1 2024.
• Average Medicaid daily rates increased by 7.5% due to state reimbursement increases and participation in supplemental Medicaid payment and quality improvement programs.
• Interest expense decreased by $9.2 million, or 57.1%, to $6.9 million, primarily due to a reduction in amounts drawn on the line of credit and long-term debt.
• Days sales outstanding decreased by 3.6 days to 53.9 days, indicating improved collections on accounts receivable.
• The company believes its current cash balances and cash flow from operations will be sufficient to cover operating needs for at least the next 12 months.

Negatives

• Net income decreased by 18.5% to $28.380 million in Q1 2025, despite substantial revenue growth.
• Operating income declined by 26.3% to $48.140 million, indicating pressure on operational efficiency and profitability.
• The overall occupancy rate for skilled nursing services decreased to 89.2% from 91.1% year-over-year.
• Ramping facilities experienced significant declines in skilled nursing services revenue (-38.0%), skilled mix by revenue (-13.6%), skilled mix by nursing patient days (-9.9%), and occupancy rate (-8.6%).
• Average Medicare daily rates decreased by 0.8% for Q1 2025 compared to Q1 2024.
• General and administrative expenses more than doubled, increasing by $51.8 million (110.5%), largely due to $22.8 million in legal fees for investigations and $12.2 million in stock-based compensation.
• The company restated its condensed combined/consolidated financial statements for Q1 2024 due to errors in revenue recognition and lease classification.
• Management identified material weaknesses in internal control over financial reporting, specifically in the control environment and revenue recognition processes.
• Multiple ongoing regulatory investigations by the DOJ and SEC pose significant legal and financial risks, with no estimable loss or range of loss at this time.
• The company entered into several forbearance agreements with its lenders due to technical events of default under its credit facility and a master lease, which prohibits borrowing new loans during the forbearance period.
• A putative securities class action and multiple shareholder derivative actions have been filed, alleging a multi-year scheme to inflate revenue and profitability through various improper billing and referral practices.

Risks

• Dependence on reimbursement from third-party payors, with changes in patient acuity, payor mix, payment methodologies, or cost-containment initiatives potentially reducing revenue and margins.
• Risk of not being fully reimbursed under consolidated billing or bundled payments.
• Shortages of nurses and other skilled staff, or heightened competition for such personnel, could increase labor costs and lead to penalties.
• State regulation or deregulation of healthcare services and facility development could restrict growth or intensify competition.
• Compliance reviews of care, records, and billing may identify issues requiring repayments or other costs.
• Litigation and claims common in the industry could result in significant legal expenses, settlements, damages, or losses under self-insurance programs.
• A material weakness in internal control over financial reporting, or failure to remediate or maintain effective controls, could impair timely, accurate reporting, reduce investor confidence, expose the company to penalties, and harm stock value.
• Inconsistent quality of care or staff misconduct could harm patients, trigger civil or criminal penalties, and damage the business.
• Failures or interruptions in information technology could disrupt operations.
• Inability to complete acquisitions at attractive prices or at all, and divestitures of underperforming or non-strategic assets could reduce revenue.
• Unforeseen costs, liabilities, or regulatory issues may arise from acquisition activity.
• Lower CMS or private quality ratings could negatively affect the business.
• Limited availability or higher cost of insurance, and self-insurance programs may expose the company to significant and unexpected costs.
• Concentration of facilities in certain regions increases vulnerability to local economic downturns, regulatory shifts, or natural disasters.
• Union activity may adversely affect revenue and profitability.
• Risks from lease terminations, renewal negotiations, and special charges due to leasing most facilities.
• Insufficient cash flow for debt, mortgage, or lease obligations could cause defaults and cross-defaults, risking loss of facilities or foreclosures.
• Founders' personal guarantees on certain leases increase default risk to them.
• The company may require additional capital to fund operations and growth, and such capital may be unavailable or available only on unfavorable terms.
• Operating in a highly regulated industry, noncompliance or regulatory change could require significant expenditures or operational changes.
• Founders' majority ownership and related governance arrangements concentrate control, limiting shareholders' ability to influence corporate matters.
• As a controlled company under NYSE rules, the company may rely on governance exemptions, potentially offering fewer protections to stockholders.
• The outcome of ongoing DOJ and SEC investigations is uncertain and could result in damages, fines, penalties, restitution, other monetary liabilities, sanctions, settlements, or changes to business practices.
• Legal costs associated with responding to regulatory investigations and SEC investigations can be substantial, regardless of the outcome.
• Inability to estimate a loss or range of loss for ongoing investigations and legal actions due to early stages and unresolved factual issues.
• Ongoing litigation, including securities class action and shareholder derivative actions, alleging a multi-year scheme to inflate revenue and profitability, could result in large jury verdicts and settlements.
• Disagreement with a landlord regarding the exercise window for purchase options on three facility operating leases.

Future Outlook

The company expects patient and resident service revenue to continue to represent the vast majority of total revenue and to increase with the successful execution of its acquisition strategy. Cost of services and rent-cost of services are also expected to increase with business growth and facility expansion. General and administrative expenses are projected to increase in absolute dollar terms due to growth investments and public company costs, though the company anticipates leveraging these expenses over time. Management believes current cash balances and cash flow from operations will be sufficient for at least the next 12 months, but may seek additional capital for future growth. The outcome of ongoing investigations and legal proceedings cannot be predicted, and there is no assurance that remediation efforts for internal control weaknesses will be sufficient or that additional material weaknesses will not be identified.

Management Comments

• "We believe our significant historical growth has been primarily driven by our expertise in acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care skilled nursing facilities."
• "We believe our success is driven in significant part by our decentralized, local operating model, through which we empower local leaders at each facility to operate their facility autonomously and deliver excellence in clinical quality and a superior experience for our patients."
• "We are in active discussions with the Required Lenders regarding the terms of an amendment and waiver to our Amended and Restated Credit Facility and expect to reach an agreement before the end of the forbearance period to be able to borrow additional amounts."
• "We believe our current cash balances and our cash flow from operations will be sufficient to cover our operating needs for at least the next 12 months."
• "We are committed to maintaining a strong internal control environment."
• "Management believes that the condensed consolidated financial statements included in this Quarterly Report fairly present, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented, in accordance with U.S. GAAP."
• "Management does not believe the results of such litigations would have a material adverse effect on the results of operations, financial position or cash flows of the Company, taken as a whole."

Industry Context

The company operates in the post-acute care industry, which is an essential component of the healthcare delivery ecosystem, serving high-need, medically fragile patients. The industry is evolving due to an aging population, increasing life expectancies, and a shift towards lower-cost care settings. Skilled Nursing Facilities (SNFs) play an integral role, providing higher-acuity care at lower costs than hospitals. The industry is highly fragmented, with approximately 15,000 facilities, creating opportunities for larger providers to consolidate. Demand for SNFs is growing and outpacing supply, as the number of facilities has declined in recent years. The reimbursement environment has been favorable, with Medicare and Medicaid rates steadily increasing over the past few years. However, the industry is highly regulated, and changes in laws or interpretations can significantly impact operations and costs.

Comparison to Industry Standards

• The company's Mature facilities achieved a high average QM Star rating of 4.1 and an occupancy rate of 96% as of March 31, 2025, which it believes demonstrates the success of its acquisition strategy.
• The SNF industry in the U.S. comprises approximately 15,000 facilities, with the top 10 operators representing about 11% of the total, indicating a highly fragmented market with many smaller, independent operators.
• Medicare reimbursement per patient day in the industry increased at a CAGR of approximately 3.6% from 2012 to 2021, while Medicaid reimbursement per patient day increased at a CAGR of approximately 1.9% during the same period. The company's average Medicaid rates increased by 7.5% in Q1 2025, which is above the historical industry CAGR.

Management Changes

Corporate Governance

Legal Proceedings

• **DOJ Civil Investigative Demands (CIDs):**
• April 8, 2024: CID to Providence Administrative Consulting Services and Paradise Valley Healthcare Center regarding alleged False Claims Act and Anti-Kickback Statute violations related to improper patient referrals.
• September 11, 2024: CID to California-based skilled nursing facilities regarding alleged False Claims Act violations related to Medicare reimbursement under the patient-driven payment model (PDPM) and Minimum Data Set Assessments.
• September 30, 2024: CID to Providence Group, Inc. regarding alleged False Claims Act violations related to Medicare reimbursement under the COVID-19 Hospital Stay Waiver (1135 waiver) at Bishop Care Center.
• February 26, 2025: Subpoena from DOJ (HIPAA related) investigating possible violations of 18 U.S.C. (fraudulent/false statements to government) concerning 1135 COVID Waiver practices, Medicare Part B billing, insurance enrollment changes, co-pay/deductible waivers, and Medicare bad debt reimbursement.
• **SEC Investigation:**
• The SEC's Division of Enforcement is conducting an investigation into the company's accounting, financial reporting, disclosure, and internal controls over financial reporting and disclosure controls.
• **Shareholder Litigation:**
• November 13, 2024: Putative securities class action (Manchin v. PACS Group, Inc., et al.) filed, alleging violations of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, claiming a multi-year scheme to inflate revenue and profitability.
• February 14, 2025: Derivative action (Howard-Hines Action) filed, alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, and contribution, based on similar allegations as the Manchin Action.
• August 19, 2025: Derivative action (Boers v. Murray, et. al.) filed, alleging substantially the same claims and theories as the IN RE PACS Group, Inc. Derivative Litigation.
• **General Litigation:**
• Subject to increasing claims and lawsuits, including professional liability, elder abuse, wrongful death, COVID-19 related claims, and class-action litigation.
• Currently involved in litigation alleging violations of state and federal wage and hour laws.
• **Lease Disagreement:**
• Options on three facility operating leases are subject to disagreement with the landlord regarding whether the option exercise window has closed.

Related Party Transactions

• The company holds a 50.0% ownership interest in BRFS SNF Ventures V, LLC, which held three post-acute care facilities operated by non-affiliated entities (operations taken over by company on August 1, 2025).
• The company holds a 25.8% ownership interest in Next Saddle Investors, LLC, which acquired operations for 53 facilities in the 2024 Prestige acquisition and leases 37 of those facilities' real estate to the company.
• Most operating leases for skilled nursing and assisted living facilities are triple-net and guaranteed by the company and/or its stockholders.
• Certain notes and loans are secured through guarantees by the company and certain stockholders.
• The company is the majority-owner in a subsidiary formed to develop land, a building, and other assets to be leased to an entity operated by the company.
• PACS Group owns subsidiaries that own real estate and related improvements leased to affiliated SNF operating entities and one non-affiliated ALF operating entity.
• PACS Group subsidiaries have equity method investments in partnerships that own real estate for 49 post-acute care facilities operated by other PACS Group subsidiaries and three operated by non-affiliated entities.
• Providence Administrative Consulting Services, Inc., a subsidiary, provides administrative support services to other PACS Group subsidiaries.
• Welsch Insurance Ltd., a wholly-owned captive insurance subsidiary, provides professional liability and general liability (PLGL) insurance coverage to various consolidated operating subsidiaries.

Stakeholder Impact

• **Shareholders:** Potential negative impact on share price due to declining profitability, restatement, material weaknesses, and extensive legal and regulatory investigations. Limited influence on corporate matters due to founders' majority ownership and controlled company status. Risk of dilution from stock-based compensation.
• **Employees:** Potential impact from operational changes resulting from regulatory actions or legal proceedings. Increased labor costs due to staffing shortages could affect compensation or job security.
• **Patients/Residents:** Potential impact on quality of care if issues like inconsistent care or staff misconduct occur, or if regulatory actions lead to operational changes.
• **Lenders:** Forbearance agreements due to technical defaults indicate increased risk and ongoing negotiations for credit facility amendments/waivers.
• **Government/Regulators:** Active and extensive investigations by the DOJ and SEC indicate significant scrutiny and potential for substantial penalties or operational changes.
• **Customers (referring providers):** Potential reputational damage from investigations and litigation could affect referral volumes.

Next Steps

• Remediate identified material weaknesses in internal control over financial reporting.
• Recruit additional compliance, legal, and internal audit personnel.
• Enhance controls related to revenue recognition, including a thorough review and approval process for new billing codes.
• Enhance the Disclosure Committee process to ensure timely information sharing impacting financial reporting.
• Cooperate with ongoing DOJ and SEC investigations to produce requested information and documentation.
• Vigorously defend against the securities class action and shareholder derivative actions.
• Reach an agreement with the Required Lenders regarding the terms of an amendment and waiver to the Amended and Restated Credit Facility.
• File the Quarterly Report on Form 10-Q for the period ended September 30, 2024, and the Annual Report on Form 10-K for the year ended December 31, 2024.
• Evaluate the impact of new accounting standards ASU 2023-09 (Income Tax Disclosures) and ASU 2024-03 (Disaggregation of Income Statement Expenses).
• Continue to execute on the acquisition strategy to identify opportunistic and strategic acquisitions.

Key Dates

Recommendation

Despite strong revenue growth, the company's profitability is declining, and it faces severe governance and compliance issues. The restatement of prior financials, identified material weaknesses in internal controls, multiple ongoing federal investigations (DOJ and SEC) into alleged fraudulent billing practices and financial reporting, and significant shareholder litigation create substantial uncertainty and risk. The need for forbearance agreements with lenders due to technical defaults further underscores financial instability and compliance failures. These factors collectively point to significant downside risk for investors, warranting a strong sell recommendation.

Keywords

Skilled Nursing Facilities, Post-Acute Care, Healthcare, Assisted Living, SEC Investigation, DOJ Investigation, False Claims Act, Internal Controls, Financial Restatement, Credit Facility, Forbearance, Shareholder Litigation, Medicare, Medicaid, Revenue Growth, Operational Expansion, Occupancy Rates